Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Azenta (AZTA) stock in plain English

Free brief · no signupStart here
AZTAPublished Nov 16, 2026
Azenta Inc
Healthcare · Medical Instruments & Supplies
Sells automated cryogenic sample management systems and consumables to research institutions.
Assets:
Automated sample storageUltra-cold freezers and cryo-management systems for biological materials
GENEWIZ multiomicsGlobal network of gene sequencing and synthesis laboratories
Three lab closuresRestructuring plan reducing multiomics facilities and workforce headcount
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

61
OPS ScoreOperating finances
Latest quote
-3.29%$47.09
$1.97B
n/a (loss)
$622.26M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was AZTA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Azenta (AZTA) do?

Azenta Inc (AZTA) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Sells automated cryogenic sample management systems and consumables to research institutions. Manages automated ultra-cold biological sample storage and offers genomic sequencing services for pharmaceutical. It is worth $1.97B on the market and sold $622.26M over the last year.

Market cap
$1.97B
P/E ratio
None (reported a loss)
Annual sales
$622.26M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 16, 2026

Brands and businesses behind AZTA

  • GENEWIZ: Provides genomic sequencing and gene synthesis services to commercial and academic researchers.
  • B Medical Systems: Manufactures vaccine refrigerators and medical-grade freezers sold to hospitals, governments, and laboratories.

AZTA’s flags, in plain English

Each flag is a number from Azenta’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Low debt

Low debt, only 4% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Stupid Cash

Can pay this year's bills 2.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 44.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -26.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about AZTA

How big is Azenta?

Azenta’s market cap is $1.97B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $622.26M: what customers paid the company over the last year, before any costs.

What is AZTA’s P/E ratio?

AZTA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with AZTA?

Tightened research budgets and muted venture funding across biotechnology clients currently reduce orders for automated instruments and lab testing. That is one risk on Azenta’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Azenta’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AZTA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card